Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Share-based Compensation (2024 - 2026)

Prelude Therapeutics' Share-based Compensation history spans 3 years, with the latest figure at $2.0 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 47.81% to $2.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.1 million, a 48.64% decrease, with the full-year FY2025 number at $11.9 million, down 44.19% from a year prior.
  • Share-based Compensation hit $2.0 million in Q1 2026 for Prelude Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Share-based Compensation for PRLD hit a ceiling of $6.1 million in Q2 2024 and a floor of $1.8 million in Q4 2025.
  • Historically, Share-based Compensation has averaged $3.9 million across 3 years, with a median of $3.8 million in 2025.
  • The widest YoY moves for Share-based Compensation: up 30.92% in 2025, down 59.11% in 2025.
  • Tracing PRLD's Share-based Compensation over 3 years: stood at $3.8 million in 2024, then tumbled by 51.14% to $1.8 million in 2025, then rose by 8.46% to $2.0 million in 2026.
  • Business Quant data shows Share-based Compensation for PRLD at $2.0 million in Q1 2026, $1.8 million in Q4 2025, and $2.4 million in Q3 2025.